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Abstract
Monkeypox virus (MPXV) causes a smallpox-like disease in humans. Clinical and epidemiological studies provide evidence of
pathogenicity differences between two geographically distinct monkeypox virus clades: the West African and Congo Basin.
Genomic analysis of strains from both clades identified a ,10 kbp deletion in the less virulent West African isolates
sequenced to date. One absent open reading frame encodes the monkeypox virus homologue of the complement control
protein (CCP). This modulatory protein prevents the initiation of both the classical and alternative pathways of complement
activation. In monkeypox virus, CCP, also known as MOPICE, is a ,24 kDa secretory protein with sequence homology to this
superfamily of proteins. Here we investigate CCP expression and its role in monkeypox virulence and pathogenesis. CCP was
incorporated into the West African strain and removed from the Congo Basin strain by homologous recombination. CCP
expression phenotypes were confirmed for both wild type and recombinant monkeypox viruses and CCP activity was
confirmed using a C4b binding assay. To characterize the disease, prairie dogs were intranasally infected and disease
progression was monitored for 30 days. Removal of CCP from the Congo Basin strain reduced monkeypox disease morbidity
and mortality, but did not significantly decrease viral load. The inclusion of CCP in the West African strain produced changes
in disease manifestation, but had no apparent effect on disease-associated mortality. This study identifies CCP as an
important immuno-modulatory protein in monkeypox pathogenesis but not solely responsible for the increased virulence
seen within the Congo Basin clade of monkeypox virus.
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Introduction
Several members of the Orthopoxvirus genus such as cowpox,
monkeypox and vaccinia viruses continue to be human pathogens
of significant worldwide concern. Variola virus, an obligate human
pathogen, was eradicated through a World Health Organization
(WHO) global immunization campaign. Prior to 1970, monkey-
pox virus was characterized as a non-human primate pathogen,
until human monkeypox cases were reported in a number of West
African countries and in the Congo Basin. Over the next several
years, WHO surveillance activities characterized a large number
of human monkeypox cases [1] in the Congo Basin country, now
known as the Democratic Republic of Congo (DRC), which
continues to have reportable monkeypox disease today [2]. The
clinical manifestations of human monkeypox were found to be
similar to those of discrete, ordinary smallpox [3]. More recently,
clinical and epidemiological evidence suggested that there were
virulence and interhuman transmissibility differences between
human monkeypox caused by West African or Congo Basin origin
viruses [4]. Furthermore, whole genome sequencing confirmed
that monkeypox viruses formed two distinct genetic groupings,
which correlated with their geographic origins, the West African
and Congo Basin clades [4,5]. In 2003, the first report of human
monkeypox disease outside of Africa occurred within the U.S.,
highlighting the potential for monkeypox virus spread into a
number of non-endemic regions, and the importance of gaining a
more detailed understanding of monkeypox [6]. In the 2003 U.S.
outbreak, after controlling for age and vaccination status, disease
caused by a strain of West African clade monkeypox virus was
characterized as less virulent and less interhuman transmissible
than that previously ascribed to human disease caused by Congo
Basin clade viruses [4]. In a small study of non-human primates, a
similar difference in the virulence of strains from each of the two
monkeypox virus clades was described [5].
The U.S. reported cases all stemmed from the importation and
distribution of exotic pets. In these cases, human owners
contracted the disease from their infected North American
black-tailed prairie dog pets (Cynomys ludovicianus), which had been
previously co-housed with imported monkeypox virus-positive
African rodents [6,7]. Subsequent research characterized mon-
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Role of CCP in Monkeypox Pathogenicity
PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e35086keypox virus challenge of prairie dogs as a useful animal model for
systemic orthopoxvirus infection, causing a rash illness with a
disease progression similar to systemic human disease [8]. This
model also recapitulates aspects of the differences in virulence
between the two monkeypox virus clade viruses.
Genomic comparisons of strains from the Congo Basin and
West African clades revealed multiple deletions and fragmenta-
tions of open reading frames in the West African strains of
monkeypox virus that may contribute to its reduced virulence. Of
note, the more virulent Congo Basin clade strains of monkeypox
virus encode a homologue of the vaccinia virus complement
control protein (CCP), annotated as C3L, while the West African
clade strains do not [4,5]. Although the monkeypox virus CCP
homolog is truncated compared to the vaccinia virus CCP, studies
have shown it retains certain complement inhibitor function [9].
The complement system is a non-adaptive network of cell-
associated and secreted effector proteins that are important to the
initiation of an inflammatory response. The two primary routes by
which complement is activated are the classical and alternative
pathways. Both of these pathways lead to the formation of the C3
convertase complex, which is composed of either C4b and/or C3b
proteins. These C3 convertases proteolytically cleave the ever-
present C3, resulting in further deposition of C3b, assembly of
more C3 convertases and formation of the C5 convertase. This
convertase cleaves C5 to C5b, which is necessary for formation of
the membrane attack complex. The activation of complement
leads to coating of virus particles with complement for the
potential lysis of enveloped viral particles and virus-infected cells.
The complement system is also important in virus neutralization
by coating the exterior of viral particles with C3b, marking it for
phagocytosis by macrophages and dendritic cells, and thus
stimulating the presentation of antigens to the adaptive immune
system. It has also been documented that this C3b coating
prevents efficient attachment and entry of the viral particle into
host cells [10]. Several cleavage products of the complement
cascade, such as C3a and C5a, are chemotactic mediators
involved in the recruitment of pro-inflammatory granulocytes
and lymphocytes to the site of infection [11,12,13].
CCP homologues have been identified in vaccinia virus, known
as VCP (vaccinia virus complement control protein); variola virus,
known as SPICE (smallpox inhibitor of complement enzymes);
ectromelia virus; and cowpox virus where it is referred to as IMP
(inflammation modulatory protein) [13,14,15,16,17,18]. These
homologues are capable of inhibiting complement through protein
binding and serving as a co-factor in cleavage of the C3b and C4b
moieties and accelerating the decay of convertases in both the
classical and alternative pathways [9,14,15,19,20,21,22,23,24].
The complement control protein homologue in vaccinia virus,
VCP, is the prototypical poxvirus mimic of the mammalian
regulators of complement (RCA) class of proteins. Like members
of the RCA family, VCP is composed of four repeating short
consensus repeats (SCR) with 30–40% identity to human RCAs
[13,14]. It is a major secreted protein in vaccinia-infected cells and
inhibits early steps in complement activation [13,14,19,20]. Due to
the presence of SCR4, VCP also exhibits C3-convertase decay
accelerating activity, resulting in a more rapid breakdown of these
protein complexes, which are an integral part of the complement
cascade [9,12]. In several experiments, it was found that VCP was
able to protect vaccinia virus against host complement-mediated
neutralization [20,25]. Vaccinia mutants lacking VCP displayed a
measurable attenuation in its pathogenicity when intradermally
injected in mice, rabbits and guinea pigs [20,26,27]. The CCP
homologue in monkeypox virus is truncated early in the fourth
SCR due to a single nucleotide deletion that results in chain
termination [5]. Lacking the complete 4th SCR region, the
monkeypox homologue lacks the C3 convertase decay accelerat-
ing activity found in VCP but retains C3b and C4b cofactor
functions [9].
The inhibition of host complement pathways by viral CCPs is
believed to abrogate the recruitment of pro-inflammatory cells to
the site of initial infection, and slow the development of a robust
host response to the pathogen [28,29,30]. The ability of a virus to
secrete a protein which impairs the early innate immune response
of the host to the developing infection would improve the ability of
the virus to maintain viability in the host. The inclusion of CCP in
the more virulent Congo Basin clade of monkeypox, and the lack
of this gene product in the West African clade, thus makes it a
protein which hypothetically may determine virulence differences
between the two clades.
To understand the role of CCP in monkeypox disease
pathogenesis, we constructed recombinant viruses, one incorpo-
rating the CCP gene under its native promoter in the West
Figure 1. Constructs used for recombinant virus formation. Plasmid maps of pABgpt and pCDgpt illustrate the recombination sites within
ROC 2003 and USA 2003 genomes. For both recombinant strains, gpt expression was controlled by a synthetic early-late promoter sequence. In the
recombinant USA+CCP, the ccp gene was under its own native promoter from ROC 2003, and the insert was located in the non-coding region
between open reading frames 177 and 176 of USA 2003.
doi:10.1371/journal.pone.0035086.g001
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35086Figure 2. In vitro expression of CCP. BSC-40 cells were infected with the parental monkeypox virus (ROC 2003 or USA 2003), the recombinant
monkeypox virus (ROCDCCP or USA+CCP), or vaccinia WR. At 24 hpi, supernatants (A) and cell lysates (B) were harvested and probed with polyclonal
a-VCP antibody. Complement control protein homologues in monkeypox virus (,24 kDa) and vaccinia WR (,35 kDa) were detected. Human
transferrin (85 kDa) was used as the load control for each well. Numerical values below each lane in blots A and B represent the intensity value of the
band using the Image Lab 3.0 band density tool. Each lane was loaded with (3 mg/ml) concentrated supernatant or cell lysate. BSC-40 cells were
infected with either the ROC 2003 strain of monkeypox virus or vaccinia WR and supernatant was harvested and replaced with fresh media at the
indicated times (C). The harvested supernatants were analyzed using a polyclonal a-VCP antibody. VCP expression was first detected in cell
supernatants at 10 hpi and monkeypox CCP expression at 24 hpi. BSC-40 cells were infected with the parental monkeypox virus (ROC 2003 or USA
2003), the recombinant monkeypox virus (ROCDCCP or USA+CCP), or vaccinia WR in the presence (+) or absence (2) of Ara-C. At 24 hpi, supernatants
(D) were harvested and probed with polyclonal a-VCP antibody. Expression of CCP in the presence/absence of Ara-C in the West African recombinant
monkeypox strain was similar to the Congo Basin strain.
doi:10.1371/journal.pone.0035086.g002
Figure 3. C4b binding activity of monkeypox virus CCP. Assay measuring the binding of MPXV complement control proteins from the media
of infected cells to human C4b. Solid triangles and squares show binding activity of USA+CCP and ROC 2003, respectively, to C4b (solid lines) or to
control wells with BSA alone (dashed lines). Open triangles and squares show binding activity of USA and ROCDCCP, respectively, to C4b. Also
graphed is a known concentration of rVCP (star symbol with dashed line) from which we estimated the amount of MPXV CCP in the media of infected
cells. The starting amount of rVCP was 2.5 ng (1.75 nM) and was then similarly diluted 2-fold. The error bars in this figure were smaller than the
symbols.
doi:10.1371/journal.pone.0035086.g003
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PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35086African/USA monkeypox virus and one removing the gene from
the Congo Basin monkeypox virus strain. Western blot analysis
confirmed the absence of CCP in the Congo Basin recombinant
and the presence of CCP in the West African recombinant. We
evaluated the virulence of the Congo Basin deletion mutant in
comparison to its parental strain and to the recombinant West
African clade expressing CCP to its parental strain using the black-
tailed prairie dog challenge model [8]. The data presented here
will provide a greater understanding of the pathogenesis of
monkeypox virus, the importance of CCP for monkeypox
virulence, and identify targets for effective vaccine design strategies
and anti-viral treatments.
Results
Construction of ROCDCCP and USA+CCP
Two plasmid constructs were made, one to incorporate CCP in
the West African USA 2003 strain, and one to remove the gene
from the Congo Basin ROC 2003 strain. The insertion of the CCP
gene into USA 2003 clade was only begun after careful
consideration and discussions with the institutional biosafety
committee, the institutional animal care and use committee, and
the select agent program. Approval was obtained since insertion of
the gene encoding the CCP into the strain of virus that lacked its
expression was an appropriate control to determine its function in
virulence. Development of the ROCDCCP and USA+CCP
recombinant viruses required the incorporation of the selectable
gpt gene marker from the pelP1-gpt vector. The gpt expression
cassette was placed under the control of a vaccinia-derived
synthetic early-late promoter (Figure 1). The complement control
protein in ROC 2003 was knocked out by double homologous
recombination at two flanking loci, deleting the gene and
simultaneously conferring mycophenolic acid resistance to the
recombinant. The USA+CCP recombinant was created by
incorporating the Congo Basin strain CCP gene under the control
of its predicted upstream promoter into the intergenic region
between ORFs 176 & 177 (Figure 1).
Recombinants were analyzed for second site mutations by
whole genome sequencing. Comparison of the USA+CCP genome
(10,890 reads) to the published sequence showed one single
nucleotide polymorphism (SNP) and one single nucleotide
deletion, with neither located in coding or promoter regions.
Mapping the sequencing reads from ROCDCCP to the published
ROC 2003 genome resulted in two contiguous sequences (contigs)
(11,779 reads) separated by the deleted CCP region. Nucleotide
comparisons revealed two SNPs. These SNPs affected a gene
fragment of the A-type inclusion (ATI) protein causing an Asp to
Val change at amino acid position 388 and a Val to Asp at
position 386. These SNPs occurred in a repeat rich region of the
truncated protein. It has been previously established that
monkeypox viruses do not produce A-type inclusion bodies due
to a frameshift mutation that causes premature truncation [4,31].
Studies where the ati gene in cowpox virus was knocked out and
compared to wild-type in mice have demonstrated limited effects
on pathogenesis, adding to its classification as a non-essential
protein product [32]. Since these two SNPs are within a truncated,
non-essential gene, the alterations should not have a significant
effect on the systemic disease pathogenesis of this recombinant.
Phenotype confirmation of the recombinants and in vitro
expression and biologic characterization
Complement control protein expression in the USA+CCP
recombinant and its absence in the ROCDCCP knockout
recombinant were evaluated by Western blot. Cell extracts and
Figure 4. Monkeypox growth curve. Single step growth curves of the parental (ROC 2003, USA 2003) and recombinant (ROCDCCP, USA+CCP)
monkeypox virus strains. No statistically significant differences were identified between the strains (p.0.05).
doi:10.1371/journal.pone.0035086.g004
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35086supernatants were prepared from infected BSC-40 cells at
24 hours post infection (hpi). The cell extracts and supernatants
(concentrated ,5X) were probed with rabbit-derived polyclonal
antisera targeted against the vaccinia complement control protein
(Figure 2A, 2B). Vaccinia-infected cell supernatants and cell
extract samples were treated similarly to provide a positive control.
In Western blot analysis, the expected size difference between the
35 kDa vaccinia CCP homologue and 24 kDa CCP in ROC 2003
and USA+CCP strains was readily apparent. CCP was not evident
in the concentrated supernatants of ROCDCCP or USA 2003-
infected cells and the presence of CCP was equivalent in the cell
extracts or concentrated supernatants from USA+CCP and ROC
2003-infected cells (Figure 2A and 2B). Quantification of the
secreted monkeypox CCP (USA+CCP or ROC 2003), based on
Western blot, was approximately five times lower than that
detected from vaccinia WR infected cell supernatants (Figure 2A).
There was similar accumulation of CCP within the ROC 2003
and USA+CCP cell extracts versus the vaccinia cell extract
(Figure 2B). Importantly, there were no significant differences in
CCP levels (supernatant or cell extract) between the ROC 2003
and USA+CCP recombinant at 24 hours post infection.
To determine at what stage of infection CCP was expressed, we
used Ara-C, which results in the inhibition of late protein
expression [33]. Cells were infected with either the ROC 2003
strain of monkeypox virus or vaccinia WR in the presence or
absence of Ara-C, and supernatant was harvested and replaced
with fresh media at the indicated times (10, 24, and 36 hpi,
Figure 2C). The collected supernatants (,5X concentrated) were
analyzed by Western blot using a polyclonal anti-VCP antibody.
Samples taken at earlier times (2, 4, and 6 hpi) were negative for
CCP and VCP expression in the absence of Ara-C (data not
shown). Growth of the virus from 6 to 10 hpi, allowed sufficient
time for VCP to accumulate and be detected by Western blot,
meanwhile monkeypox CCP expression was absent. In the sample
collected at 24 hpi, the monkeypox homologue was first detected
(Figure 2C). The addition of Ara-C eliminated the ability to detect
VCP and monkeypox CCP by Western blot at any time point
(data not shown). To evaluate the expression of monkeypox CCP
in the USA+CCP recombinant, we chose a single time point
(24 hpi) that based upon our time course experiment would have a
sufficient amount of CCP expression. Western blots of superna-
tants (,5X concentrated) from BSC-40 cells infected with
USA+CCP MPXV, ROC 2003 MPXV, or vaccinia WR in the
presence/absence of Ara-C were probed with anti-VCP rabbit
polyclonal sera (Figure 2D). We found that USA+CCP and ROC
2003 accumulated similar levels of secreted CCP at 24 hours
(Figure 2D). The CCP gene in USA+CCP is expressed at late
times and likely under the control of the predicted upstream late
promoter, derived from the ROC 2003 strain of monkeypox virus,
contained within the construct.
We compared the biological activity of the secreted complement
control protein from the USA+CCP strain and the ROC 2003
strain, using a C4b binding activity assay (Figure 3). This assay
determined the ability of concentrated virus supernatants
containing CCP to interact with human C4b coated on a
microtiter plate. The monkeypox-infected cell supernatants, from
ROC 2003 or USA+CCP infections, manifested equivalent levels
of C4b binding (Figure 3). No C4b binding activity was seen in the
supernatants from cells infected with either the ROCDCCP or
USA strains of MPXV.
To further evaluate whether the recombination manipulations
affected the biologic properties of the viruses, relative to their
growth kinetics, viral one step growth curves were compared. Over
72 hours, no significant differences in growth kinetics were
observed between the recombinant and the parental viruses
(Figure 4).
Monkeypox prairie dog challenge
Previous work with black-tailed prairie dogs (Cynomys ludovicianus)
has demonstrated that monkeypox virus challenge of this species
provides an animal model that resembles many aspects of human
systemic orthopoxvirus disease [5,7,8]. Four challenge groups,
Figure 5. Monkeypox disease progression timeline. Depiction of the comparative disease progression of the four challenge monkeypox strains
in the prairie dog animal model. This diagram highlights monkeypox disease as observed lesions progressed from a local to systemic infection and
eventual resolution. Note the slower progression of disease in the ROCDCCP-infected group when compared to its ROC 2003 parental group. The
USA+CCP-infected prairie dogs displayed earlier subjective signs of infection when compared to the USA 2003 group.
doi:10.1371/journal.pone.0035086.g005
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with 4610
5 pfu of ROC 2003, ROCDCCP, USA 2003 or
USA+CCP in a total volume of 10 microliters. This dose was ,3
times greater than the LD50 for the West African strain
(1.29610
5 pfu) and ,70 times greater than the LD50 for the
Congo Basin strain (5.9610
3 pfu) in prairie dogs [34]. All animals
were observed daily for signs of illness, with weight measurements,
swabs, and blood samples taken every other day for the duration of
the study (30 days).
Deletion of CCP in the Congo Basin clade virus slows the
disease course and minimizes disease mortality
Similar to previous observations using the intranasal route of
infection [8], the first observable presentation of illness was nasal
swelling and lesions in the oral cavity (Figure 5). In animals
challenged with the recombinant ROCDCCP, there was a delay in
illness onset. ROC 2003 challenged animals manifested nasal
swelling at day 6 (2 of 4 animals) and primary lesions (all 4 animals)
consisting of several flat, circular macules on the tongue and palate
between days 8–10. In contrast, animals challenged with
ROCDCCP manifested nasal swelling later; only one animal
showed any nasal swelling at day 8, and primary oropharyngeal
lesions did not develop until day 10 (Figure 5, Table 1).
Viable virus and viral DNA was detected in the oral cavity as
early as day 2 and remained for several days (Figures 6A, 7A),
persisting after the development of orthopoxvirus-specific anti-
bodies beginning on day 12 (Figure 8) in ROC 2003-infected
animals. Similar to observation of delayed onset of oropharyngeal
lesions, viable virus and viral DNA was detected only after day 4 in
ROCDCCP infected animals (Figures 6A, 7A).
Viral DNA was detected in whole blood of ROC 2003-infected
animals at day 4, and not until day 6 in ROCDCCP infected
animals. The overall level of viral DNA in whole blood, on
average, was lower in ROCDCCP infected animals than in ROC
2003-infected animals. (Figure 7D). ROC 2003-infected animals
developed a disseminated, vesiculo-pustular rash between days 10–
12, with average lesion sizes measuring 5 mm in diameter
appearing on the back, abdomen, armpit and hindleg regions of
the prairie dogs (Table 1). The ROC 2003-infected prairie dogs
developed secondary lesions on multiple sites, such as the back,
armpits, and abdominal area; lesions were also observed on the
footpads of all prairie dogs. In some animals, pustules developed
Figure 6. Viable monkeypox virus loads. Mean live virus titers for the oral (A), ocular (B), and anal (C) swabs taken from each animal in a given
infection group in the prairie dog challenge study. Note that all animals in the ROC 2003 group were dead by day 16. Also, by day 16 there were only
two remaining animals in the USA 2003 group and starting on day 20, there were only two remaining animals in the USA+CCP group. Dark bar
borders indicate n,4 for the mean generated on that day. The mean viral titer for each infection group was graphed with standard deviations. Unless
indicated by an asterisk, group comparisons within sampling days were not significantly different (p.0.05).
doi:10.1371/journal.pone.0035086.g006
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genitals of two male animals. In most ROCDCCP infected
animals, secondary or generalized lesion onset was delayed with
respect to the observations within the ROC-infected cohort,
although in one ROCDCCP infected animal (PD17) we observed
the appearance of a secondary lesion on its neck on the same day
as its first oral lesion (day 10). Secondary lesions were found in the
other ROCDCCP-infected prairie dogs between days 12–14
(Figure 5, Table 1), with a similar lesion distribution as seen in
the ROC 2003-infected animals, but the lesion load was less than
what was documented in the ROC 2003-infected animals
(Table 1).
Twelve days post-infection it was evident that weight loss in the
ROC 2003 group was occurring more rapidly and at a greater
magnitude than any of the other challenge groups with 17%
weight loss vs 8% for ROCDCCP, 13% for USA 2003 and 11%
for USA+CCP on this day (Figure 9). One animal was euthanized
on this day (PD18) due to inappetence, lesion severity, lethargy,
and labored breathing. The condition/health of the remaining
animals in this group rapidly declined as an additional prairie dog
was euthanized on day 14 (PD10) and the remaining two animals
were euthanized by day 16, due to a combination of disease
symptoms such as lethargy, labored breathing, and inappetence
including .25% weight loss for PD9 (Figure 9, Table 1). Both
viable virus and viral DNA were first detected on day 2 and
persisted until the death of each animal (Figures 6 & 7, Table 1).
Upon necropsy, viable virus was detected at varying levels in all
sampled tissues with peak amounts found within the kidney for all
four animals (Table 2).
Conversely, the ROCDCCP-infected cohort demonstrated
resolution of disease; weight gain reinitiated between days 18
and 20, by day 16 all lesions had scabbed over, and by day 22
most of the crusts had fallen off, leaving hypopigmented scars on
the skin. Prior to euthanasia of the ROC-infected animals, there
were no significant differences between the viable viral loads in
oral, ocular or anal excreta of ROCDCCP-infected and ROC
2003-infected animals on any day of the study, except for oral
swabs taken on day 12 post-infection (p=0.03) (Figure 6A, B, &
C). On this particular sample day, the ROCDCCP-infected cohort
average viable virus load was lower than that of the wild-type
ROC-infected cohort. The average oral and ocular shedding of
viable ROCDCCP virus peaked day 10, and consistently
decreased until it was undetectable after day 22 (Figure 6A and
6B). Anal swabs detected viable ROCDCCP through day 20 with
peak average shedding occurring on day 16. The duration of
viral shedding cannot be compared to the wild-type ROC
Figure 7. Monkeypox virus DNA loads. Mean viral DNA by real-time PCR for the oral (A), ocular (B), anal (C) and blood (D) samples collected from
each animal in a challenge group. Dark bar borders indicate n,4 for the mean generated on that day. The mean viral DNA for each infection group
was graphed with standard deviations. Group comparisons within sampling days were not significantly different (p.0.05).
doi:10.1371/journal.pone.0035086.g007
Role of CCP in Monkeypox Pathogenicity
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e350862003-infected animals since these succumbed to disease by day 16
post-infection, however the ROCDCCP-infected animals demon-
strated shedding of viable virus longer than seen for the USA-
infected animals (Table 1 and Figure 6). The ROCDCCP-infected
cohort displayed slower weight loss than the wild-type ROC-
infected cohort. Linear regression analysis of the average weight
loss data from the highest to the lowest weight indicated that the
slope of the ROC 2003-infected animals was significantly higher
than in ROCDCCP group (p=0.03). The analysis also showed
that the average weight loss in the ROCDCCP group was not
significantly different from the USA 2003 group (p=0.69). These
findings highlighted the fact that on average the ROC 2003-
infected animals displayed signs of greater disease severity (such as
rapid weight loss) than the ROCDCCP-infected prairie dogs.
Although not statistically significant, all ROCDCCP-infected
prairie dogs seroconverted to the highest level of any of the four
groups in the challenge study (Figure 8). At necropsy, no viable
virus was found in any of the tissues from the ROCDCCP-infected
animals (Table 2) but weak positives for viral DNA were detected
in the following tissues of at least two animals in this group: lungs,
heart and kidney (data not shown).
Addition of CCP in the West African clade virus does not
markedly accelerate clinical disease course, variably
affects virus shedding and does not affect disease
mortality
Prairie dogs infected with USA 2003 did not show any signs of
infection until day 10 when the first macules appeared on the
tongues and palates of 2 animals (PD4 and PD16) (Figure 5). Only
animals in the USA+CCP group exhibited the early symptom of
nasal swelling on day 6 (PD12) and on day 8 (PD7) (Figure 5).
Macular lesions appeared on the tongue or palate in all animals on
day 10, similar to that observed with the USA 2003-infected
prairie dogs.
Within the USA 2003 infected group, on day 10, one of the
prairie dogs (PD2) in this group did not wake up post-anesthesia.
PD2 did not demonstrate lesion development or other overt signs
of disease on day 10, and did not have significant weight loss
(,10%, Figure 9), and had very low viable virus levels in tissues
upon necropsy (Table 2), suggesting its death most likely was due
to complications with anesthesia and not related to monkeypox
infection.
Unexpectedly, viable virus was detected relatively early (Day 2)
in the oral swab of one USA 2003-infected animal (PD16), and in
others by day 4. Viral excreta in ocular or anal swabs of animals
infected with USA 2003 were not observed until day 6 and
persisted in surviving animals out to day 14 for ocular swabs and
day 18 for anal swabs (Figure 6). Viral DNA persisted longer than
viable virus in oral, ocular and anal excreta samples (Table 1,
Figures 6 and 7). Viral DNA was detected within the blood as early
as 4 days post-infection and persisted until 22 days post-infection
(Figure 7D). Animals challenged with the USA+CCP virus began
to excrete virus in the oral, ocular and anal samplings on days 4, 6
and 8 respectively. After day 10, measured viable virus and DNA
loads were consistently lower than that observed in the USA 2003-
infected animals in the oral, ocular and anal swabs with the only
exception being on a day 18 DNA oral swab (Figures 6 and 7).
Viral DNA was detected in whole blood on day 6, persisted
through day 16 and levels were less than that observed in USA
2003 infected animals throughout the study (Figure 7D). However,
none of these differences in viable virus or viral DNA load were
statistically significant.
Figure 8. Anti-orthopoxvirus antibody production. Orthopoxvirus specific ELISA to detect total IgG. The average value per infection group is
shown here. The reported OD-COV (cutoff value) corresponds to the value above the average signal of the negative control wells plus two standard
deviations. None of the average OD-COVs were significantly different between groups within a sample day (p.0.05). Dark bar borders indicate n,4
for the mean generated on that day.
doi:10.1371/journal.pone.0035086.g008
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12 and 14 on the anus of all USA 2003-infected animals and the
genitals of two male prairie dogs. On day 14, PD4 was euthanized
due to inappetence, lethargy, and labored breathing (Figure 5,
Table 1). By day 16 all observed lesions became umbilicated and
began to scab over; by day 24 most of the lesions had resolved
leaving patches of hypopigmentated skin. As seen in the USA
2003-infected group, the USA+CCP-infected animals did not
develop many secondary lesions, a few were found in the mouth or
around the anus and these lesions were first identified on day 12
(Table 1). On day 18, two of the animals (PD12 and PD15) were
euthanized due to lethargy, inappetence and labored breathing,
along with weight loss near the euthanasia limit (Figure 9B). The
rate of weight loss was similar for both the wild-type USA 2003-
infected cohort and the USA+CCP-infected cohort. Linear
regression analysis of the average weight loss data from the
highest to the lowest weight showed no significant difference
between the slopes of USA 2003 and USA+CCP-infected animals
(p=0.49).
Upon necropsy of the USA 2003-infected animals, viable virus
was detected in the lungs, heart, kidney and spleen of PD4 who
was euthanized on day 14, while in PD2, the animal who did not
revive after anesthesia on day 10, viable virus was detected in the
heart, lung, spleen and eyelid samples (Table 2). At necropsy, no
viable virus was found in any of the tissues from the animals who
survived the viral challenge, although low levels of viral DNA was
present in the oral swabs of PD6 and PD16 (Figure 7).
Upon necropsy of the USA+CCP-infected animals that were
euthanized on day 18 post-challenge (PD12 and PD15), viable
virus was recovered from the lungs, kidney, liver and spleen.
Viable virus was found in the liver of USA+CCP or ROC2003-
infected animals who did not survive to day 30, but was not found
in the liver of USA2003-infected PD4, which was euthanized on
day 14 of the challenge study. At the day 30 necropsy of the
survivors of the USA+CCP infection, no viable virus was found in
any of the tissues, but there was a weak positive DNA signal
detected in the eyelid sample of one animal (PD6).
Discussion
The goal of this study was to determine if the proposed
immunomodulatory effect of the monkeypox CCP was a major
contributor to the documented disease differences between the
West African and Congo Basin clades of monkeypox virus. To
investigate the role of CCP in monkeypox virulence, we deleted it
from the more virulent ROC 2003, a Congo Basin strain, and
incorporated it into the less virulent USA 2003, belonging to the
West African clade. The selectable marker, gpt, has been used in
Figure 9. Prairie dog weight graphs. Percent weight loss graph for all four infection groups, USA 2003 (A), USA+CCP (B), ROC 2003 (C), and
ROCDCCP (D). Each prairie dog within their respective infection group was listed with a different symbol according to legend.
doi:10.1371/journal.pone.0035086.g009
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presence in the recombinants has the potential to be a limitation in
this study, hence we conducted a C4b assay to confirm normal
CCP activity and growth curve to demonstrate normal growth
kinetics of the recombinants. The experimental design was
discussed with multiple institutional ethics oversight committees
prior to its execution. It was important to investigate the addition
of CCP to the USA 2003 strain to better frame the scientific
question regarding disease manifestations influenced by the
presence or absence of CCP within these strains of monkeypox
viruses. Due to several gene truncations/deletions in the West
African strain, we sought to determine if the addition of a single
virulence-associated gene was sufficient to impact its pathogenesis.
We confirmed by single-step growth curves that the mutations
introduced in the recombinant viruses had no effect on the in vitro
infectivity and growth of the virus. Using a C4b-binding ELISA,
we confirmed that the CCP produced by the USA+CCP had the
same activity as the CCP naturally expressed by ROC 2003.
Liszewski, et al. reported that recombinant forms of VCP (rVCP)
and the MPXV CCP had approximately the same C4b binding
activity [9]. Using the rVCP as a standard and the concentrated
supernatants from MPXV-infected cells, we estimated that the
concentration of CCP in the media of infected cells to be
,0.12 mg/ml. This estimation assumes that the activity or the
protein in the supernatant of infected cells is similar to purified
recombinant proteins. Through the Ara-C experiment, we also
provided evidence that VCP and CCP were proteins expressed at
the late stages of infection. VACV-infected cells produced more
VCP than monkeypox-infected cells produce of its homologue
(Figure 2A).
The parental and recombinant strains of virus were used in the
prairie dog animal model, which has proven to be a reproducible
model capable of distinguishing disease differences between the
two clades of monkeypox virus [5]. The intranasal route of
infection mimics an upper respiratory exposure, which is an
important route of transmission [35]. Similar to intradermal
infections of mice, guinea pigs, and rabbits with VCP-knockout
virus [20,26,28], the ROCDCCP group of infected animals
displayed a marked reduction in disease severity, and in this study
they produced fewer disseminated lesions with no mortality. The
linear regression analysis of the weight loss data further highlights
the reduced disease severity seen in the ROCDCCP-infected
group when compared to the wild-type ROC 2003-infected group.
The loss of CCP significantly reduced the rate of weight loss
compared to ROC 2003-infected group (p=0.03) and made the
weight loss kinetics more closely resemble that observed in USA
2003-infected animals (p=0.69). The only other difference in the
rate of weight loss that neared 95% statistical significance was
between wild-type ROC 2003-infected and wild-type USA 2003-
infected groups (p=0.057). The ROCDCCP-infected group also
appeared to have delayed signs of disease, with the onset of nasal
swelling and primary lesions beginning later than the ROC 2003-
infected group (Figure 5). ROCDCCP-infected animals excreted
similar quantities of virus (Figure 6) at ‘‘peak’’ times post-infection
when compared to ROC 2003 despite less severe disease with
lower rash burden (Table 1). Detection of viral DNA in the blood
of ROCDCCP-infected animals was delayed and reduced with
respect to parental ROC 2003-infected animals (Figure 7), perhaps
indicating that the loss of CCP reduced the ability to suppress
elements of the innate response, enabling the hosts to localize the
infection, thus increasing time until systemic viral disease.
The ROCDCCP recombinant-infected prairie dogs elicited the
strongest humoral immune response of all monkeypox virus strains
tested (Figure 8). Since all of the ROC 2003 animals succumbed to
disease by day 16, we were unable to compare the magnitude of
humoral immune response, persistence of viable virus and
possibility for shedding/transmission between the ROC 2003
and ROCDCCP groups. However, consistent with previous
studies [8], the duration of viable virus excretion/viremia for the
ROCDCCP-infected animals was greater than that seen for USA
2003-infected animals, indicating other factors besides CCP affect
the overall potential for shedding (and thus potentially transmis-
Table 2. Viable virus in animal necropsy tissue samples in plaque-forming unit per gram of tissue.
Strain
Animal
Number Death/Euthanasia Heart Lungs Spleen Kidney Liver
Lymph
node Gonad Eyelid
ROC 2003 PD8 16 50,331 410,048 178,922 495,522 1,110 389 19,343 18,485
PD9 16 34,258 94,949 391,403 2,012,146 2,083 1,131 22,448 6,510
PD10 14 124,812 960,938 1,138,393 2,586,957 31,154 24,258 203,284 898,785
PD18 12 317,588 359,512 430,380 953,737 9,785 704 160,887 284,211
ROCDCCP PD5 30 000 0 0 000
PD11 30 000 0 0 000
PD13 30 000 0 0 000
PD17 30 000 0 0 000
USA 2003 PD2* 10 586 383 671 0 0 0 0 11,856
PD4 14 19,704 5,865 39,488 8,347 0 0 0 0
PD6 30 000 0 0 000
PD16 30 000 0 0 000
USA+CCP PD7 30 000 0 0 000
PD12 18 0 8,651 21,073 33,879 8,916 0 0 0
PD14 30 000 0 0 000
PD15 18 0 19,335 5,670 13,158 14,431 0 0 0
*Death due to anesthesia.
doi:10.1371/journal.pone.0035086.t002
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were able to avoid the severe morbidity, increased mortality and
increased weight loss associated with the Congo Basin infection
and instead manifested a disease progression more similar to the
USA 2003-infected animals (Figures 5, 6 & 9). The data presented
here demonstrates that the monkeypox CCP homologue is a
significant immunomodulatory protein for Congo Basin clade
virulence. Our data also suggests that deletion of CCP from ROC
2003 renders the virus susceptible to clearance by the innate and
adaptive immune system, and permits a robust adaptive immune
response to virus infection.
Notably, the inclusion of CCP in the West African clade
monkeypox virus did not enhance its virulence to levels
comparable to that of the Congo Basin clade viruses, but appeared
to accelerate development of some signs of the disease course.
Overall, the mortality and morbidity associated with the USA
2003+CCP recombinant infections were within expected ranges
estimated by the LD50 for the USA 2003-infected animals [34].
When compared to the USA 2003-infected animals, there did
appear to be some earlier signs of localized, ‘‘primary’’ disease,
such as the observation of nasal swelling in PD12 (day 6, 8) and
PD7 (day 8), the progression of disease in this regard is similar to
the ROC 2003-infected group (Figure 5). Other than earlier nasal
involvement, all other later, generalized signs of disease remained
unchanged from the USA 2003 group; for instance there was not
an appreciable increase in the onset of, or number of, lesions
(Table 1). Furthermore, the duration of viable virus shedding in
oral swabs was almost indistinguishable (Figure 6), providing
greater evidence that the presence of CCP does not influence the
potential for shedding/transmission of the virus. The presence of
CCP may affect the tissue tropism and pathogenesis, the virus was
found in the liver only in euthanized animals infected with either
USA+CCP or ROC 2003 (Table 2). This remains a preliminary
observation as none of the ROCDCCP infected animals were
euthanized during the disease course.
The prairie dog model system is useful because of the similarity
to human systemic orthopoxvirus disease, and potential extrapo-
lations to understanding human disease. However, the use of
outbred animals does make experimental designs to achieve
statistical significance, if outcome differences are subtle, challeng-
ing. For instance, in order to detect a significant difference
(p,0.05) in the linear regression slopes of the weight loss in the
USA 2003 vs. USA+CCP groups, we would have to reach a
statistical power of 80% which would require 67 animals per
group.
Our data indicates other factors besides CCP are necessary to
significantly increase disease virulence. Although there are
differences, this is a conclusion also reached by another group
when testing a CCP knockout monkeypox virus recombinant in
the non-human primate model [36]. Homologues to several other
virulence factors such as the myxoma virus M-T4, anti-apoptosis
protein and B14R, interleukin-1 binding protein are also missing
from the West African clade genomes and are inferred to be
involved in determining disease pathogenesis and virulence [5].
However, our data with the West African clade parental and
recombinant viruses additionally suggests that the presence of
CCP may have an effect on the host adaptive immune response as
antibody levels were lower in the two surviving USA+CCP-
infected animals versus the two surviving USA 2003-infected
animals (Figure 8).
These results also highlight CCP’s importance as a potential
target for immunotherapy. A strain of vaccinia virus lacking VCP,
yet possessing all the other major antigenic epitopes, may be a
promising vaccine due to its reduced virulence and potential to
elicit a stronger immune response. Others have described the use
of monoclonal antibodies (mAbs) to block the activity of the CCP
homolog, SPICE, found in variola virus [37]. Monoclonal
antibodies directed against CCP [25,37] and possibly several
other established virulence-related proteins [38] may prove to be
effective in treating infected individuals.
Finally, an observation of this study which may impact the use
of viral DNA measurements to track disease course and the effect
of disease interventions was that all sampling group measurements
of viral DNA had similar kinetics to that of viable virus. However,
viral DNA persisted much longer than viable virus within the
samples (Figures 6 and 7). The RT-PCR assay is likely to detect
DNA fragments as well as genomic DNA belonging to intact viral
particles, thereby viral DNA observed later during infection may
be due to the clearing of the infection. A better understanding of
what the presence of viral DNA signifies will be critical to
determining its utility as a biomarker for studies evaluating vaccine
or therapeutic efficacy.
This study demonstrates CCP expressed by ROC 2003, an
example of the Congo Basin clade of monkeypox virus, is a
virulence factor that significantly affects clinical disease progres-
sion, weight loss and mortality in the prairie dog animal model
system. However, its expression in the West African clade virus,
represented by USA 2003, is insufficient to elicit equivalent levels
of disease comparable to the Congo Basin clade in this model
system. These viruses have divergent evolutions [4], possibly due
to different reservoir or susceptible host species, and thus may have
developed different virulence mechanisms. Regardless, removal of
CCP from the Congo Basin virus clade significantly reduced the
morbidity and mortality associated with disease.
Materials and Methods
Parental Viruses and Cell lines
The West African strain of monkeypox virus used for these
experiments was MPXV-USA-2003-044 (USA 2003). This isolate
was collected during the 2003 monkeypox outbreak in the USA
from the lymph node of an infected prairie dog associated with the
initial human case in Wisconsin [4]. The Congo Basin strain of
monkeypox virus, MPXV-ROC-2003-358 (ROC 2003), was
isolated from the rash of a 10-year-old girl infected in Impfondo,
Republic of Congo, and admitted to the hospital on June 9, 2003
[39]. Both monkeypox strains were passaged three times prior to
working stock production. Supernatant containing VCP produced
by low-passage, Vaccinia virus Western Reserve (VACV WR) was
utilized for comparisons to monkeypox CCP. BSC-40 cells [40],
grown in RPMI 1640 containing 10% sterile-filtered, fetal bovine
serum (FBS) were used for all cell culture infections and isolations
of all parental and recombinant virus strains, unless otherwise
specified.
Recombinant gpt
+ Virus Construction
All work was approved by the Institutional Biosafety Committee
and the Select Agent office prior to the initiation of these
experiments. The selectable genetic marker used for isolation was
the Escherichia coli xanthine-guanine phosphoribosyltransferase or
gpt gene, which confers resistance to growth inhibitor, mycophe-
nolic acid [41,42].
The CCP gene plus 123 bp of the upstream region was PCR
amplified from ROC 2003 with primers CCP1, 59-GTC GAC
CTC ATA AGT C AC TGC CAT TGT TTT-39 and CCP2, 59-
GGA TCC CAT TGT AGT TGT ATG AGT GT A TG-39 using
Platinum High Fidelity DNA Polymerase (Invitrogen, Carlsbad,
CA), then ligated into the pZsGreen expression vector at the SalI
Role of CCP in Monkeypox Pathogenicity
PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e35086and BamHI sites for the construction of pCDgpt. This insert was
positioned into plasmid pCDgpt (Figure 1) adjacent to the gpt gene
under the control of a vaccinia-derived, synthetic early-late
promoter, 59-GCA TAT GTA AAA GTT GAA AAT ATA
TTT CTA TGC TAT AAA TA-39 [43] and flanked by sequences
homologous to the 765 bp non-coding intergenic region between
ORFs 176 and 177 (annotated as type I membrane hemagglutinin
and serine/threonine kinase, respectively) in the USA 2003 strain.
Plasmid pABgpt (Figure 1) contained the synthetic early-late
promoter controlling the gpt gene with upstream and downstream
flanking regions homologous to ORFs 21 and 23 (annotated as
unknown protein and kelch-like gene fragment, respectively) from
the ROC 2003 genome.
The two plasmid constructs were integrated into their host
genomes through an infection-transfection protocol. BSC-40 cells
in RPMI+2% FBS are seeded in 6-well Costar plates (Corning
Inc., Corning, NY) 24 hours prior to the experiment, with an
average confluency of ,80% per well. The cells are washed in
Opti-MEM media, then either ROC 2003 or USA 2003 sucrose
cushion-purified virus was added to each well at a MOI=0.05.
The viruses were incubated at 36uC, 6% CO2 for 2 hours, and
then replaced with Lipofectamine 2000 (Invitrogen) in Opti-MEM
and 4 mg of the plasmid DNA of interest (pABgpt or pCDgpt) for
72 hours.
Virus plaques were purified using mycophenolic acid as the
selection agent [41,42]. The recombinant viruses successfully
expressing xanthine-guanine phosphoribosyl-transferase were se-
lected by growth in BSC-40 cells in 2X DMEM supplemented
with 2% FBS, 25 mg/ml mycophenolic acid, 250 mg/ml xanthine,
10 mg/ml thymidine, 15 mg/ml hypoxanthine and 2 mg/ml
aminopterin (Millipore, Phillipsburg, NJ). Each recombinant strain
was plaque purified four times in a 25 mg/ml mycophenolic acid
plus 2% agarose overlay containing 3% neutral red, and collected
using a Pasteur pipet after incubation at 36uC, 6% CO2 for
72 hours.
The West African recombinant strain of monkeypox virus,
MPXV-USA-2003-044, in which CCP was incorporated into its
genome through homologous recombination, was designated
USA+CCP. The CCP knockout recombinant derived from the
Central African strain, MPXV-ROC-2003-358, was designated
ROCDCCP. Each recombinant clone was sequenced using 454
sequencing in the CDC Biotechnology Core Facility to ensure the
genomes were free of second site mutations.
Complement control protein expression
BSC-40 cells were infected with VACV WR, ROC 2003, USA
2003, ROCDCCP, or USA+CCP virus, at a MOI=10 in Opti-
MEM at 36uC, 6% CO2 for 1 hour. The media was removed and
replaced with Opti-MEM (Invitrogen, Carlsbad, CA) then
incubated for 24 hours at 36uC and 6% CO2. The supernatants
were decanted into a centrifuge tube and then spun at 10006g
for 10 min to remove cell debris. After UV inactivation for
2 min. at 25uC, all harvested supernatants were subjected to ,5-
fold concentration (by volume) using the Ultracel YM-10
Centricon protein concentration columns (Millipore, Phillips-
burg, NJ) with a 10 kDa molecular weight cut-off. Centricons
were spun at 50006g for 10 min at 25uC and filtrate discarded,
retentate was collected at 10006g for 2 min at 25uC. To harvest
the cell lysates, the infected-cell monolayers were washed twice
with Opti-MEM, and then RIPA buffer was added to the cells,
which were then incubated at 4uC for 5 min (Thermo Scientific,
Rockford, IL). The cells were collected and spun at 14,0006gf o r
15 min at 4uC.
Western blot analysis
For Western blot analysis, the above virus-infected cell
supernatants and cell lysate samples were boiled for 5 min. in
Laemmli loading buffer containing 2% sodium dodecyl sulfate and
2-mercaptoethanol (Bio-Rad Laboratories, Hercules, CA). All
supernatant and cell lysate samples (3 mg/ml per well) were loaded
onto a 12% precast Tris-glycine polyacrylamide gel (Bio-Rad
Laboratories, Hercules, CA) and then run at 150 volts for 1 hour.
Protein bands were transferred at 100 mA for 50 min to
polyvinylidene fluoride (PVDF) membranes using a Mini-blot
protean II chamber (Bio-Rad Laboratories, Hercules, CA). The
membranes were incubated in blocking buffer (1% non-fat milk,
0.1% Tween 20) for 2 hours. The blots were probed with
polyclonal rabbit anti-VCP antibody (courtesy of Dr. John
Lambris, University of Pennsylvania) at a 1:1000 concentration
for approximately 12 hours on a 10 rpm rocker at 4uC. The blots
were also probed with polyclonal rabbit anti-transferrin at 1:1000
to confirm to that wells received an equivalent load of protein.
After the blot was washed with PBS containing 0.1% Tween 20,
alkaline phosphatase conjugated goat anti-rabbit antibody (1:3000)
(Bio-Rad Laboratories, Hercules, CA) was added to the blot for
2 hours and the chemiluminescent signal detected using Chemi-
Doc XRS+ (Bio-Rad Laboratories, Hercules, CA).
Expression of the complement control protein
BSC-40 cells were infected with VACV WR or ROC 2003 at
MOI=10 in Opti-MEM with or without 10 mg/ml cytosine
arabinoside [Ara-C] (Sigma-Aldrich, St. Louis, MO) at 36uC, 6%
CO2 for 1 hour. The media was aspirated, cells washed twice with
5 ml of the appropriate media, and then 7 ml of the corresponding
media was added to each flask and incubated at 36uC, 6% CO2.
Infected cell supernatants were collected at 2, 4, 6, 10, 24 and
36 hours post-infection (hpi) and replaced with fresh correspond-
ing media after each harvest (Figure 2C). Ultracel YM-10
Centricon protein concentration columns were used to concen-
trate the harvested vaccinia and monkeypox supernatants. The
samples were spun at 50006 g for 10 min at 25uC and filtrate
discarded, retentate was collected at 10006g for 2 min at 25uC.
Samples were analyzed by Western blot as described above.
To compare the temporal expression of CCP between ROC
2003 and USA+CCP strains, we repeated the above experiment
using those strains and VACV WR as a control in the presence/
absence of 10 mg/ml Ara-C. Infected cell supernatants were
harvested at 24 hours post-infection, then the vaccinia and
monkeypox supernatants were ,5X concentrated by Centricon,
and all samples were analyzed by Western blot (Figure 2D).
Band intensities were measured using the Image Lab 3.0
software band density tool (Bio-Rad Laboratories, Hercules, CA).
Complement control protein C4b binding assay
C4b ELISAs were performed as described in the literature [9].
Briefly, Maxisorb ELISA plates (Nunc, Rochester, NY) were
coated with human C4b (Complement Technologies, Tyler,
Texas) at 5 mg/ml in PBS overnight at 4uC and then blocked
for 2 hours at 37uC (5% BSA (Sigma A2934) and 0.1% Tween 20
in PBS). Concentrated supernatants (,5X) from cells infected with
ROC 2003, ROCDCCP, USA 2003, or USA+CCP were serially
diluted in low salt ELISA buffer (10 mM Tris (pH 7.2), 25 mM
sodium chloride, 0.05% Tween 20, 4% BSA, and 0.25% Nonidet-
P40), added to wells in duplicate, and incubated for 1 hour at
37uC. Plates were then washed in low salt ELISA buffer (but not
containing BSA), and rabbit anti-VCP (diluted 1:5000 in low salt
ELISA buffer) was added for 1 hour at 37uC. Following washing, a
peroxidase-conjugated donkey anti-rabbit IgG (diluted 1:8000 in
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developed using TMB substrate (Invitrogen) and read at an OD of
450 nm. Data shown is the average of two experiments (Figure 3).
A standard curve using rVCP (starting amount 2.5 ng) [9]
(courtesy of Dr. John Atkinson, Washington University of School
of Medicine) was also run in this assay to estimate the amount of
MPXV CCP in the supernatant of infected cells.
Single Step Growth Curve
Confluent monolayers (.95%) of BSC-40 cells in six-well plates
were infected, in duplicate, with a MOI=5 of ROC 2003, USA
2003, ROCDCCP, or USA+CCP virus in RPMI 1640+2% FBS
then incubated at 36uC and 6% CO2 for 1 hour. The inoculum
was removed and replaced with 1 mL fresh RPMI 1640+2% FBS
media. Virus was harvested from the cells at 2, 6, 12, 18, 24, 36,
48, and 72 hours post-infection and stored at 270uC. On day of
titration, the aliquots were freeze-thawed 3 times prior to serially
diluting the samples and plating on six-well plates of BSC-40 cells.
After 72 hour incubation, plates were stained with crystal
violet+2% formalin and individual plaques were counted
(Figure 4).
Prairie dog challenge experiment
All animal work was conducted according to relevant national
and international guidelines. The experimental designs and ethics
of the study were discussed with the institutional biosafety
committee, the institutional animal care and use committee, and
the select agent program. Animals were cared for in accordance
with the CDC Institutional Animal Care and Use Committee
(IACUC) approved protocol 1431REGPRAC-A4. Wild-caught,
juvenile black-tailed prairie dogs (Cynomys ludovicianus) were
obtained from western Kansas. The animals were captured
shortly after adolescence in 2004 and at the time of infection the
prairie dogs had been in captivity for 4 years. During experimental
infections, animals were housed individually in
12.130623.38069.000 cages with aerosol filter tops (Thoren
Caging Systems, Hazleton, PA). Cages were kept in a Duo-Flow
biosafety cabinet (Lab Products, Inc. Seaford, DE) in the BSL-3
animal room. Animal handling was performed using BSL-3
personal protective equipment. Throughout the study, animals
were maintained in a 12 hour light/12 hour dark cycle, and in
addition to standard prairie dog chow (Exotic Nutrition Pet Co.,
Newport News, VA), the animals were provided with monkey
biscuits (Exotic Nutrition Pet Co., Newport News, VA) for dietary
enrichment.
Prairie dogs weighing between 875–1250 grams were infected
intranasally with 4610
5 pfu of ROC 2003, USA 2003,
ROCDCCP, or USA+CCP while under inhaled anesthesia (5%
isoflurane mixed with air). There were 4 animals in each of the
monkeypox virus-challenged groups. The intranasal inoculum,
titered at the time of challenge, was administered in a total volume
of 10 ml1 6 PBS, with each nostril receiving 5 ml of inoculum.
Every 2 days swabs were taken from the mouth, anus and eye of
each prairie dog under isoflurane anesthesia using sterile
individual Dacron swabs (Epicentre Biotechnologies, Miami, FL)
and stored at 270uC without diluent. In addition, 200 ml of whole
blood was collected from the lateral saphenous or jugular vein in
EDTA coated tubes (Vetlab Supply Inc., Miami, FL) for real-time
PCR and viable virus assessment of total viral load; 100 ml was
harvested in serum separating tubes (Becton, Dickinson and Co.,
Franklin Lakes, NJ) for serological analysis. On these sample days
the weight and temperature of each prairie dog was recorded and
tracked throughout the study. Any notable visual observations or
occurrences were also documented on sampling days. For
euthanasia criteria, we observed individual animals for the
following signs of illness severity: inappetence (3 pts), labored
breathing (5 pts), unsteady gate (3 pts), lack of responsiveness to
touch (5 pts), and lethargy (3 pts). Points were given for each of
these signs, any animal accruing a score indicative of severe illness
($10 pts.) was humanely euthanized. In addition, any animal
losing greater than 25% of their starting body weight was
euthanized regardless of other clinical symptoms.
The planned length for this study was 30 days; if death did not
occur prior to the end of the challenge experiment, animals were
humanely euthanized and necropsied. Necropsies on all animals
were performed according to IACUC standards in a BSL-3
laboratory and utilizing full BSL-3 personal protective equipment.
Samples taken during necropsy, not including the swab and blood
samples, were from the following sites: eyelid, heart, lung, liver,
spleen, kidney, mesenteric lymph node, and gonad. Instruments
(scalpel, scissors, forceps, etc.) were cleaned and decontaminated
with 30% Lysol (Reckitt Benckiser Inc., Parsippany, NJ) and 10%
bleach (Fisher Scientific, Pittsburgh, PA) between collections of
each tissue. Tissues were frozen at 270uC prior to further
processing.
Sample Processing
All sample processing took place in the BSL-2 laboratory with
BSL-3 practices. In order to analyze viral DNA in the blood,
water was added as needed to bring the total volume to 200 ml,
and the samples were incubated at 55uC for 1 hour. The EZ-1
DNA extraction robot (Qiagen, Valencia, CA) was used for viral
DNA extraction of all collected blood samples using the tissue
extraction protocol provided by the manufacturer. For all swabs
collected during the challenge study, 400 ml PBS was added to
the microfuge tube, incubated at room temperature for
,5 minutes and then the swab extraction tube systems (SETS)
(Roche, Indianapolis, IN) protocol was used to recover sample
from the swab. A 100 ml aliquot of swab eluant was incubated in
lysis buffer and proteinase K at 55uC for one hour prior to
extraction of genomic DNA using the EZ-1 DNA extraction
robot (Qiagen, Valencia, CA). For all virus strains, the remaining
swab lysate was used for virus isolation. There was no viable virus
isolation from the prairie dog whole blood samples due to
technical difficulties.
Necropsy tissue samples were homogenized to slurry using a
metal ball tissue grinder (SPEX SamplePrep LLC, Metuchen, NJ).
Genomic DNA was prepared from a 100 ml slurry aliquot using
the EZ-1 DNA extraction robot, after incubation in lysis buffer
and proteinase K for 1 hour as described above. Remaining
necropsy tissue sample slurry was used for virus isolation.
Real-time PCR analysis
All swab, blood, and necropsy samples were analyzed in
duplicate by real-time PCR using forward and reverse primers and
probe complementary to the highly conserved orthopoxvirus DNA
polymerase gene, E9L [8,44].
Virus titration
Swab and necropsy samples that tested positive for the presence
of orthopoxvirus DNA using the real-time PCR assay were
evaluated for the presence of viable virus through growth in BSC-
40 cells. These samples were titrated by tenfold dilution of the
swab eluent/tissue slurry in RPMI+2% FBS media and incubated
with the cells at 36uC and 6% CO2 for 72 hours. Cells were
stained with crystal violet+2% formalin and then the plaques were
counted.
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ELISA assays were used to analyze the collected blood for the
presence of anti-orthopoxvirus-specific IgA and IgG. Ninety-six
well microtiter plates were coated with 0.01 mg/well crude
vaccinia virus-BSC40 cell lysate in carbonate buffer on one half
of the plate and an equivalent volume of BSC-40 cell material
diluted in carbonate buffer on the other half; plates were incubated
overnight at 4uC. The plates were inactivated by incubating in
10% buffered formalin at room temperature for 10 min., after
which they were blocked for 30 min at room temperature with
assay diluent (PBS, 0.01 M, pH 7.4+0.05% Tween-20, 5% dried
skim milk, 2% normal goat serum and 2% BSA) and washed in
PBS plus 0.05% Tween-20. Experimental prairie dog sera (1:100)
was added to both halves of the plates and incubated for 1 hour at
37uC. Each plate was washed in PBST and ImmunoPure A/G
conjugate (Pierce, Rockford, IL) was added at 1:30,000 and then
incubated for 1 hour at 37uC. Plates were then washed and a
peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithers-
burg, MD) added; image development took approximately 5–
15 min. Stop solution was added and the absorbance was read on
a spectrophotometer reading at 450 nm. All reported values
represent the average of two wells of the same sample. Specimens
were considered positive if the test sample absorbance was above
the cut-off value (COV). The COV was determined averaging the
cell lysate half of each plate and adding two standard deviations
[8].
Genomic sequencing
Sequencing of the ROCDCCP and USA+CCP genomes was
carried out using standard protocols of the Genome Sequencer
FLX pyrosequencing platform (Roche Applied Science, Indianap-
olis, IN) using the shotgun sequencing protocol.
Statistical analysis
As data were not normally distributed, nonparametric statistical
analyses were used [45]. Using the Wilcoxon rank-sum test,
reported data averages were compared within sample day between
the following groups, ROC 2003 vs. ROCDCCP and USA 2003
vs. USA+CCP. All P-values lower than 0.05 were considered
significantly different.
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